These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9127893)

  • 21. Live dysentery vaccine "Vadizen" (T32-Istrati) immunogenicity against Shigella-like challenge in animals.
    Ciudin L; Meitert T; Pencu E; Gheorghe G; Tonciu M; Mihai I; Manase R
    Arch Roum Pathol Exp Microbiol; 1986; 45(3-4):247-56. PubMed ID: 3300598
    [No Abstract]   [Full Text] [Related]  

  • 22. Current aspects of Shigella pathogenesis.
    Torres AG
    Rev Latinoam Microbiol; 2004; 46(3-4):89-97. PubMed ID: 17061529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cell-free polyvalent Shigella vaccine.
    Tamura JT
    J Infect Dis; 1967 Dec; 117(5):353-9. PubMed ID: 6078217
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficiency of immunoprophylaxis and immunotherapy by live dysentery vaccine administration in children and adults collectivities.
    Meitert T; Ciudin L; Pencu E; Tonciu M; Gheorghe G
    Arch Roum Pathol Exp Microbiol; 1982; 41(4):357-69. PubMed ID: 6763515
    [No Abstract]   [Full Text] [Related]  

  • 25. [Experimental model of keratoconjunctival infections in the study of immunity against Shigella].
    Cefalù M; Puglisi C
    G Mal Infett Parassit; 1972 Apr; 24(4):281-9. PubMed ID: 5050309
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
    Levine MM; Kotloff KL; Barry EM; Pasetti MF; Sztein MB
    Nat Rev Microbiol; 2007 Jul; 5(7):540-53. PubMed ID: 17558427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials of Shigella vaccines in Israel.
    Cohen D; Ashkenazi S; Green M; Gdalevich M; Yavzori M; Orr N; Robin G; Slepon R; Lerman Y; Block C; Ashkenazi I; Taylor D; Hale L; Sadoff J; Schneerson R; Robbins J; Wiener M; Shemer J
    Adv Exp Med Biol; 1996; 397():159-67. PubMed ID: 8718595
    [No Abstract]   [Full Text] [Related]  

  • 28. [Research on active immunity of man in bacillary dysentery. 3. Maintenance of the non-pathogenic character of the Shigella flexneri 2a TXXXII strain orally administered to volunteers].
    Istrati G; Meitert T; Ciufeco C
    Arch Roum Pathol Exp Microbiol; 1965 Sep; 24(3):677-86. PubMed ID: 5877879
    [No Abstract]   [Full Text] [Related]  

  • 29.
    Schnupf P; Sansonetti PJ
    Microbiol Spectr; 2019 Mar; 7(2):. PubMed ID: 30953429
    [No Abstract]   [Full Text] [Related]  

  • 30. Recent advances in modelling Shigella infection.
    Miles SL; Holt KE; Mostowy S
    Trends Microbiol; 2024 Sep; 32(9):917-924. PubMed ID: 38423917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.
    Cohen D; Green MS; Block C; Rouach T; Ofek I
    J Infect Dis; 1988 May; 157(5):1068-71. PubMed ID: 3283258
    [No Abstract]   [Full Text] [Related]  

  • 32. [Stimulation of antidysentery immunity with acetoxan].
    Gorbunova ES
    Antibiotiki; 1966 Apr; 11(4):354-8. PubMed ID: 4861976
    [No Abstract]   [Full Text] [Related]  

  • 33. Shigellosis.
    Niyogi SK
    J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and administration of live Shigella vaccines.
    Pencu E
    Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):231-50. PubMed ID: 6443689
    [No Abstract]   [Full Text] [Related]  

  • 35. Live-attenuated Shigella vaccines.
    Venkatesan MM; Ranallo RT
    Expert Rev Vaccines; 2006 Oct; 5(5):669-86. PubMed ID: 17181440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The response of man to virulent Shigella flexneri 2a.
    DuPont HL; Hornick RB; Dawkins AT; Snyder MJ; Formal SB
    J Infect Dis; 1969 Mar; 119(3):296-9. PubMed ID: 5780532
    [No Abstract]   [Full Text] [Related]  

  • 37. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide.
    Cohen D; Green MS; Block C; Slepon R; Lerman Y
    J Infect Dis; 1992 Apr; 165(4):785-7. PubMed ID: 1552217
    [No Abstract]   [Full Text] [Related]  

  • 38. Progress and pitfalls in Shigella vaccine research.
    Barry EM; Pasetti MF; Sztein MB; Fasano A; Kotloff KL; Levine MM
    Nat Rev Gastroenterol Hepatol; 2013 Apr; 10(4):245-55. PubMed ID: 23419287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How Do the Virulence Factors of
    Mattock E; Blocker AJ
    Front Cell Infect Microbiol; 2017; 7():64. PubMed ID: 28393050
    [No Abstract]   [Full Text] [Related]  

  • 40. Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery.
    Phalipon A; Sansonetti P
    Biologicals; 1995 Jun; 23(2):125-34. PubMed ID: 7546655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.